Diffusion-weighted MR imaging in prediction of response to neoadjuvant chemotherapy in patients with breast cancer

Xue-Ying Hu1,*, Ying Li1,*, Guan-Qiao Jin1, Shao-Lv Lai1, Xiang-Yang Huang1 and Dan-Ke Su1

1 Department of Radiology, Guangxi Medical University Affiliated Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region, China
* Authors contributed equally to this work

Correspondence to: Dan-Ke Su, email: doctorsu0771@sina.com

Keywords: MRI, apparent diffusion coefficient, neoadjuvant chemotherapy, breast cancer

ABSTRACT

This study aims to evaluate the potential of apparent diffusion coefficient (ADC) derived from diffusion-weighted MR imaging for predicting the treatment response to neoadjuvant chemotherapy (NACT) in patients with breast cancer. Magnetic resonance imaging was performed prior to NACT and after two cycles of NACT. The correlation between mean ADCpre values, mean ADCpost values, changes in ADC values and changes in tumor diameters after NACT was examined using Spearman rank correlation. A total of 164 breast cancers were enrolled in this study. Mean ADCpre values of responders ([0.85 ± 0.16] × 10⁻³ mm²/s) and non-responders ([0.84 ± 0.21] × 10⁻³ mm²/s) had no significant difference (P = 0.759). While mean ADCpost value of responders was significantly higher than that of non-responders ([1.17 ± 0.37] × 10⁻³ mm²/s vs. [1.01 ± 0.28] × 10⁻³ mm²/s; P = 0.002). Both mean ADCpost values (r = 0.288, P = 0.000) and changes in mean ADC values (r = 0.222, P = 0.004) were positively correlated to changes in tumor diameter after NACT, except for mean ADCpre values (r = 0.031, P = 0.695). Our results indicated that mean ADCpost values and changes in ADC values after NACT might be a biological marker for assessing the efficacy of chemotherapy.

INTRODUCTION

Neoadjuvant chemotherapy (NACT) is well known to routinely used as standard treatment of breast cancer [1, 2], with the clinical aims of reducing the size of tumors, down staging the disease, improving operative rates, and improving overall survival by the prompt treatment of distant metastases [3, 4]. The accurate and reliable evaluation of response to NACT plays an important role in post chemotherapeutic optimal management, avoiding unnecessary therapy and minimizing drug-related side effects. Traditionally, the evaluation of tumor response has been assessed via tumor size measurements such as clinical examination, X-ray mammography, and ultrasound [5]. However, the assessment of treatment response via the above measurements is considered a relative late event since molecular and cellular changes occur prior to alterations in tumor size [6]. Therefore, a reliable assessment that can provide an earlier indication of therapeutic response is of pivotal importance.

Magnetic resonance imaging (MRI) has been widely used in breast imaging and has been reported as a more effective method for assessing disease extent than physical examination and/or other imaging modalities. And dynamic contrast-enhanced (DCE) MRI has been regarded as a relatively effective tool for assessing tumor progression and/or responses to chemotherapy. DCE-MRI depicts the tumor more accurately through providing information about blood flow and vessel permeability. However, DCE-MRI which is a morphological MR imaging has suboptimal potentiality to distinguish the viable tumor tissue from the tissue of scar, necrosis, fibrosis, and reactive inflammation, and may lead to misestimate the residual tumor size [7, 8]. This potentially yields false positive results and contributes...
to misrecognize a proportion of responder patients. Therefore, assessing tumor response to NACT could not only depend on DCE-MRI.

Diffusion-weighted (DW) MR imaging is a relatively recent MR imaging sequence that exploits the Brownian motion of water molecules. This technique can be used to measure apparent diffusion coefficients (ADCs)—a quantitative measure of the diffusivity of water—provides information related to tumor cellularity and the integrity of cell membranes and is sensitive to intratumoral changes induced by chemotherapy [9-12]. Nowadays, it was reported in several studies that DW-MRI may be used to evaluate treatment response to NACT in breast cancer patients [13-17]. However, the sample sizes are relatively small and the discriminative ability of a metric tends to be overestimated in those published literatures [13-17]. Therefore, the role of DWI on evaluating the efficacy of chemotherapy in breast cancer still needs further verification. This study aims to assess ADC values in DW-MRI combination with DCE-MRI for evaluating treatment response to NACT in breast cancer patients.

MATERIALS AND METHODS

Patients

This study was a retrospective one and was approved by our institutional review board. All patients had signed consent form that their data were used in this study. A total of 164 breast cancer participants were consecutively included in this study. Tumor histology of breast cancer diagnosis and details of estrogen and progesterone receptors were confirmed by core needle biopsy before NACT. All these patients had received NACT before surgery and examined by breast DCE-MRI (1.5T) with DWI before the first cycle of NACT (baseline MRI) and after two cycles of NACT (follow-up MRI) between July 1st 2012 and July 30th 2016. Patients with a metastatic disease or a combination with other cancers which were confirmed by chest X-ray or CT, liver ultrasound or CT, as well as bone scan were excluded.

According to histological classification of breast cancer, 164 cases were comprised of 155 invasive ductal carcinomas, 1 invasive micropapillary carcinoma, 3 invasive lobular carcinomas, 3 metaplastic carcinomas, and 2 unknown. Pre-chemotherapy clinical stages included 4 cases of I, 28 cases of IIA, 76 cases of IIB, 32 cases of IIIA, 10 cases of IIB, and 14 cases of IIIC. The characteristics of patients were presented in Table 1. All breast cancer patients underwent 4-8 cycles of NACT with the different chemotherapeutic regimen (docetaxel 75 mg/m² + epirubicin 100 mg/m² or fluorouracil 500 mg/m² + epirubicin 100 mg/m² on day 1 and repeated every 21 days). Appropriate surgery was performed in all patients, no matter whether they were responders or not. After the completion of surgery, adjuvant chemotherapy, radiation therapy, and/or hormone therapy were applied.

MR imaging examination

Breast MR imaging was conducted at a 1.5 Tesla (T) MR imaging system (Magnetom Avanto, Siemens Healthcare, Germany) equipped with a dedicated 8 channel phased array breast coil and subjects in the prone position [18]. The scan parameters were as the previous study [18]. The image parameters of transverse T1-weighted FLASH pulse sequence were repetition time/echo time (TR/TE; 8.6/4.7 ms), section thickness (1 mm), intersection gap (0.2 mm), field of view (32 × 32 cm²), and image matrix (323 × 448), respectively. A transverse T2-weighted TIRM pulse sequence was conducted with these image parameters: (TR/TE/inversion time [TI] ), 5600/59/180 ms; section thickness, 4 mm; intersection gap, 0.8 mm; field of view, 34 × 34 cm; and image matrix, 314 × 320. DW-MR images were acquired in transverse planes and covered both breasts with these parameters: b values, 0 and 800 s/mm²; TR/TE/TI, 5800/86/180 ms; section thickness, 6 mm; intersection gap, 0.2 mm; field of view, 32 × 32 cm; and image matrix, 323 × 448. For multiphase dynamic contrast enhancement, acquisitions were acquired before contrast agent injection and at approximately 15s after the injection of contrast agents of 0.1 mmol Gd-DTPA (Magnevist meglumine, Bayer HealthCare Pharmaceuticals, Germany) per kilogram of body weight. Eight to ten phases were ceaselessly collected and acquisition time for each phase was 55s. The injection rate was 2.0 ml/s, followed by a 20 ml saline flush.

Measurement of ADC values

DW images and contrast enhanced MR imaging results were reviewed by two experienced radiologists (Guan-Qiao Jin and Shao-Lv Lai, 12 and 16 years of experience in breast MRI, respectively) who were blinded to pathologic findings and treatment responses to NACT. Any disagreements were resolved by a third radiologist (Dan-Ke Su, 20 years of experience in breast MRI). The ADC values were derived based on the following formula: ADC = -ln[S(b1)/S(b0)], where S (b1) and S (b0) were signal intensities with (b value of 800) and without diffusion sensitizing gradients ((b value of 0), respectively. Using DCE-MR images as reference purpose, regions of interest in tumor lesions were randomly drawn to extract several circles with 5-10mm in diameter corresponding to the tumor lesion. Meanwhile, the areas with cystic, necrosis, liquefactions, or hemorrhage were excluded. The mean and average ADC were calculated for tumor lesions. The values of tumor ADC before the first
cycle of NACT (ADC\textsubscript{pre}) and after two cycles of NACT (ADC\textsubscript{post}) were measured. Changes in ADC values (ΔADC = ADC\textsubscript{post} - ADC\textsubscript{pre}) were also calculated.

**MRI assessment**

Treatment response was assessed after two cycles of NACT. Based on the DCE-MRI and Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, patients with breast cancer were divided into responders and non-responders [19]. Responders included patients who had a complete response (CR, complete reduction of tumor lesions) and/or partial response (PR, at least a 30\% reduction of the longest diameter of tumor lesions) to treatment. Non-responders included patients with stable disease (SD, less than a 30\% decrease or a 20\% increase of the longest diameters of tumor lesions) and/or progressive disease (PD, at least a 20\% increase of the longest diameters of tumor lesions) to therapy.

**Statistical analysis**

Results were presented as mean ± standard deviation (x ± SD). Age, pre- and post-NACT mean tumor diameters and ADC values, and changes in ADC values were compared between responders and non-responders using the independent-samples t test. Spearman rank correlation was carried to explore the correlation between (a) mean ADC\textsubscript{pre} values and changes in tumor diameters after two cycles of NACT, (b) mean ADC\textsubscript{post} values and changes in tumor diameters after two cycles of NACT, and (c) changes in ADC values and changes in tumor diameters after two cycles of NACT. SPSS (version 12.0; SPSS Chicago, Ill) was used to carry out all statistical analyses. A P value of less than 0.05 was considered statistically significant.

**Figure 1:** A 50-year-old woman who was responder with invasive ductal carcinoma. Before neoadjuvant chemotherapy, the lesion diameter was 5.5 cm in transverse contrast-enhanced T1-weighted image a, the apparent diffusion coefficient (ADC) value was 1.118 \times 10^{-3} \text{mm}^2/\text{s} b. After neoadjuvant chemotherapy, the lesion diameter was 3.4 cm in transverse contrast-enhanced T1-weighted image c, and the ADC value was 1.30 \times 10^{-3} \text{mm}^2/\text{s} d.
RESULTS

Characteristics of responders and non-responders

After two cycles of NACT, 164 breast cancer patients were divided into 84 cases of responders (51.2%) and 80 cases of non-responders (48.8%) according to the DCE-MRI and RECIST guidelines. There was no significant difference between responders and non-responders in terms of mean age (responders [47.7 ± 10.2 years] vs. non-responders [46.0 ± 10.1 years]; \(P = 0.0289\); Table 1), as well as mean tumor diameters at pretreatment DCE-MRI images (responders [5.2 ± 2.3 cm] vs. non-responders [4.6 ± 2.2 cm]; \(P = 0.0289\); Table 1). But pre-chemotherapy clinical stage was significantly different between responders and non-responders (I vs. IIA vs. IIB vs. IIIB vs. IIIC; \(P = 0.018\)). After two cycles of NACT, mean tumor diameter in responders was significantly smaller than that in non-responders (responders [2.0 ± 1.8 cm] vs. non-responders [4.0 ± 1.7 cm], \(P = 0.000\); Table 2).

| Characteristics                         | Responders | Non-responders | \(P\) value |
|-----------------------------------------|------------|----------------|-------------|
| Total                                    | 84         | 80             |             |
| Age (years)                             | 47.7       | 46             | 0.289       |
| Pre-chemotherapy clinical stage          |            |                | 0.018       |
| I                                        | 1          | 3              |             |
| IIA                                      | 21         | 7              |             |
| IIB                                      | 36         | 40             |             |
| IIIA                                     | 12         | 20             |             |
| IIIB                                     | 4          | 6              |             |
| IIIC                                     | 10         | 4              |             |
| Tumor histology                          |            |                | 0.431       |
| Invasive ductal carcinoma                | 77         | 78             |             |
| Invasive micropapillary carcinoma        | 1          | 0              |             |
| Invasive lobular carcinoma               | 2          | 1              |             |
| Metaplastic carcinoma                    | 3          | 0              |             |
| Others                                   | 1          | 1              |             |
| Estrogen receptor                        |            |                | 0.211       |
| Positive                                 | 52         | 58             |             |
| Negative                                 | 27         | 16             |             |
| Unknown                                  | 5          | 6              |             |
| Progesterone receptor                    |            |                | 0.238       |
| Positive                                 | 43         | 51             |             |
| Negative                                 | 36         | 24             |             |
| Unknown                                  | 5          | 5              |             |

ADC values of responders and non-responders

Before NACT, mean ADC\(_{\text{pre}}\) value of responders ([0.85 ± 0.16] \(\times 10^{-3}\) mm\(^2\)/s) and non-responders ([0.84 ± 0.21] \(\times 10^{-3}\) mm\(^2\)/s) had no significant difference (\(P = 0.759\)). After two cycles of NACT, mean ADC\(_{\text{post}}\) values significantly increased both in responders (\(P = 0.000\)) and non-responders (\(P = 0.000\)) compared with mean ADC\(_{\text{pre}}\) values. While mean ADC\(_{\text{post}}\) value of responders was significantly higher than that of non-responders ([1.17 ± 0.37] \(\times 10^{-3}\) mm\(^2\)/s vs. [1.01 ± 0.28] \(\times 10^{-3}\) mm\(^2\)/s) (\(P = 0.002\)) (Table 2 and Figure 1-2).

Mean ADC\(_{\text{pre}}\) values and changes in tumor diameter after NACT were not significantly correlated (\(r = 0.031\), \(P = 0.695\)), suggesting that there may be no correlation between mean ADC\(_{\text{pre}}\) values and changes in mean tumor diameter after two cycles of NACT. Mean ADC\(_{\text{post}}\) values were positively correlated to changes in tumor diameter after two cycles of NACT (\(r = 0.288\), \(P = 0.000\)), as well as changes in mean ADC values (\(r = 0.222\), \(P = 0.004\)). The higher the mean ADC\(_{\text{post}}\) values and the larger the changes in mean ADC values were, the more significant the changes in tumor diameter after two cycles of NACT were.
DISCUSSION

Pretreatment prediction and early monitoring of treatment response to neoadjuvant chemotherapy is of pivotal importance for developing an optimal management for breast cancer patients. In our study, mean ADC\textsubscript{pre} values of responders and non-responders had no significant difference. Our results are similar to that of the study briefly reported by Wang et al [20]. While in some previous studies concerning breast cancer, the lower the ADC\textsubscript{pre} values were, the better the treatment response achieved [13, 14]. Some other studies reported that mean ADC\textsubscript{pre} values did not predict treatment response to neoadjuvant chemotherapy [21-23]. Classically, the low diffusion values of tumors have been attributed to their increased cellular density [11]. The cellular density

| Characteristics          | Responders (n = 84) | Non-responders (n = 80) | P value |
|--------------------------|---------------------|-------------------------|---------|
| Maximal tumor diameter* (cm) |                     |                         |         |
| Pre-treatment            | 5.2 ± 2.3           | 4.6 ± 2.2               | 0.105   |
| Post-treatment           | 2.0 ± 1.8           | 4.0 ± 1.7               | 0.000   |
| ADC (× 10^{-3} mm\textsuperscript{2}/s) |                     |                         |         |
| Pre-treatment            | 0.85 ± 0.16         | 0.84 ± 0.21             | 0.759   |
| Post-treatment           | 1.17 ± 0.37         | 1.02 ± 0.28             | 0.002   |

ADCs, apparent diffusion coefficients; SD, standard deviation.
*Maximal tumor diameters were measured with DCE-MR images.

Figure 2: A 45-year-old woman who was non-responder with invasive ductal carcinoma. Before neoadjuvant chemotherapy, the lesion diameter was 3.0 cm in transverse contrast-enhanced T1-weighted image a. The apparent diffusion coefficient (ADC) value was $1.01 \times 10^{-3}$ mm\textsuperscript{2}/s b. After neoadjuvant chemotherapy, the lesion diameter was 2.8 cm in transverse contrast-enhanced T1-weighted image c, and the ADC value was $1.06 \times 10^{-3}$ mm\textsuperscript{2}/s d.
of responders may reduce compared with those of non-responders in breast cancer, which may have contributed to the higher ADCs in responders. Hence, breast cancers with higher ADC_{pre} values might be more sensitive to NACT in theory and mean ADC_{pre} value may be a good pretreatment predictor of response to NACT.

In the presented study, with a total of 164 patients undergoing NACT, mean ADC_{pre} values were not correlated to changes in tumor diameter after NACT. Our results are in accordance with that of some previous studies [22, 24]. However, some other published studies found that pretreatment ADC values were negatively correlated to treatment response [13]. The amount of necrosis and necrotic tumors which are hypoxic, acidic and poorly perfused may explain why tumors are resistance to treatment [25, 26]. Hence, questions concerning the effects of mechanisms underlying breast cancer development and biologic structural differences between breast cancer types on treatment response are worthy of further study.

Our results showed that mean ADC_{post} values significantly increased both in responders and non-responders compared with mean ADC_{pre} values, but mean ADC_{pre} values of responders increased more significantly than that of non-responders. Moreover, in our study, mean ADC_{post} values were positively correlated to changes in tumor diameter after two cycles of NACT, as well as changes in mean ADC values. These results are consistent with several previous studies [13-15] which indicated that changes in ADC values after NACT might be associated with tumor response to NACT, as mean ADC values after NACT significantly increase, breast tumor lesions may be sensitive to NACT. The mechanisms of increased ADCs after NACT are described as follows. DW image is well known as a noninvasive examination to reflect biological features of tissue through water diffusion performance shown by ADC values. Water diffusion changes after tissue damage are primarily attributed to changes in volume and curvature of extracellular space which is mainly determined by cell density [27, 28]. Chemotherapy drugs can damage cancer cells directly or indirectly, which result in changes in membrane integrity and permeability of cell membrane rupture, reducing the number of cancer cells and decreasing cancer cell density. Then the extracellular space is expanded, along with significantly increased ADC values.

Several limitations in the present study need to be caution. First, this study was a retrospective study and patients were administrated with different chemotherapeutic regimens, which may have an influence on treatment response. Second, treatment response was based on DCE-MRI measurement of tumor diameter. Although tumor histology after surgery was performed, treatment response after the second cycle of NACT was not confirmed histologically due to different course of NACT. However, both radiologist and surgeons were blinded to pathological report at the time of image analysis. Third, in our study, we set the second cycle of NACT as the time point for early monitoring treatment efficiency, in which most tumor lesions may have morphological changes. Thus, in order to explore the prediction efficiency of ADC values before the morphological change of tumor lesions, we should set an earlier time point in future study, such as 1 day or 1 cycle after NACT. Fourth, breast cancer has four distinct phenotypes and treatment response is closely associated with breast tumor phenotype. Given the small sample, we could not further evaluate the prediction efficiency between different molecular subtype and treatment response. We will further study such an association in the future researches. Fifth, we included six pre-chemotherapy clinical stages (I, IIA, IIB, IIA, IIIB, and IIIC) of breast cancer patients and found that pre-chemotherapy clinical stage was significantly different between responders and non-responders (P = 0.018) which might have some influence on our results. Further study with larger-scale was needed to explore such effects.

In conclusion, our results provide evidence that mean ADC_{post} values and changes in ADC values after NACT might be a biological marker for assessing the efficacy of chemotherapy.

ACKNOWLEDGMENTS

We thank all the people who provided technical support and useful discussion of the article.

CONFLICTS OF INTEREST

There is no conflict of interest.

GRANT SUPPORT

Guangxi Science and Technological Development Project (No. Guikegong14124004-1-11) and Guangxi Self-financing Scientific Research Subject (No. Z2013418).

REFERENCES

1. Mieog JS, van der Hege JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007; 94:1189-1200.
2. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackes R, Makris A, Miller W, Pierga JY, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007; 18:1927-1934.
3. Fisher B, Brown A, Mamounas E, Wicand S, Robidoux A, Margeolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, et al. Effect of preoperative chemotherapy on local-regional disease in...
women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15:2483-2493.

4. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkun D, King KM, Pajon ER, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26:778-785.

5. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescotti G, Zuiani C. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004; 14:1371-1379.

6. Chenevert TL, Meyer CR, Moffat BA, Rehentulla A, Mukherji SK, Gebarski SS, Quint DJ, Robertson PL, Lawrence TS, Junck L, Taylor JM, Johnson TD, Dong Q, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging. 2002; 1:336-343.

7. Lobbes MB, Prevos R, Smidt M, Tjan-Heijnen VC, van Goethem M, Schipper R, Beets-Tan RG, Wildberger JE. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging. 2013; 4:163-175.

8. Heldahl MG, Lundgren S, Jensen LR, Gribbestad IS, Bathe NF. Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T? J Magn Reson Imaging. 2011; 34:547-556.

9. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehentulla A, Ross BD. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000; 92:2029-2036.

10. Herneth AM, Guccione S, Bednarski M. Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol. 2003; 45:208-213.

11. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009; 11:102-125.

12. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000; 43:828-836.

13. Li XR, Cheng LQ, Liu M, Zhang YJ, Wang JD, Zhang AL, Song X, Li J, Zheng YQ, Liu L. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol. 2012; 29:425-431.

14. Park SH, Moon WK, Cho N, Song IC, Chang JM, Park IA, Han W, Noh DY. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology. 2010; 257:56-63.

15. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed. 2009; 22:104-113.

16. Yankeeov TE, Lepage M, Chakravarthly A, Broome EE, Niemann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging. 2007; 25:1-13.

17. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006; 24:843-847.

18. Luo N, Su D, Jin G, Liu L, Zhu X, Xie D, Liu Y. Apparent diffusion coefficient ratio between axillary lymph node with primary tumor to detect nodal metastasis in breast cancer patients. J Magn Reson Imaging. 2013; 38:824-828.

19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.

20. Wang YC, Hu DY, Hu XM, Shen YQ, Meng XY, Tang H, Li Z. Assessing the Early Response of Advanced Cervical Cancer to Neoadjuvant Chemotherapy Using Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging: A Pilot Study. Chin Med J (Engl). 2016; 129:665-671.

21. Bufl E, Beli P, Costantini M, Cipriani A, Di Matteo M, Bonastesta A, Franceschini G, Terrible D, Mulé A, Nardone L, Bonomo L. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. Clin Breast Cancer. 2015; 15:370-380.

22. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol. 2010; 49:354-360.

23. Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuramami M, Gautam S, Hatabu H, Kan S, Mountford C. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging—comparison with contrast-enhanced MR imaging and pathologic findings. Radiology. 2010; 254:357-66.

24. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry
M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer. 2006; 94:427-35.

25. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, Doran S. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet. 2002; 360:307-308.

26. Mardor Y, Roth Y, Ochershvilli A, Spiegelmann R, Tichler T, Daniels D, Maier SE, Nissim O, Ram Z, Baram J, Orenstein A, Pfeffer R. Pretreatment prediction of brain tumors’ response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia. 2004; 6:136-142.

27. Szafer A, Zhong J, Gore JC. Theoretical model for water diffusion in tissues. Magn Reson Med. 1995; 33:697-712.

28. Norris DG, Niendorf T, Leibfritz D. Health and infarcted brain tissues studied at short diffusion times: the origins of apparent restriction and the reduction in apparent diffusion coefficient. NMR Biomed. 1994; 7:304-310.